Mild Cognitive Impairment - Pipeline Review, H2 2016

Published: Sep, 2016 | Pages: 111 | Publisher: Global Markets Direct
Industry: Pharmaceuticals & Healthcare | Report Format: Electronic (PDF)

Summary

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Mild Cognitive Impairment - Pipeline Review, H2 2016, provides an overview of the Mild Cognitive Impairment (Central Nervous System) pipeline landscape.

Mild cognitive impairment (MCI) is a condition involving problems with cognitive function (such as thinking, knowing and remembering). MCI is an intermediate stage between the expected cognitive decline of normal aging and the more serious decline of dementia. Symptoms include depression, irritability and aggression, anxiety and apathy. Risk factors include diabetes, high blood pressure, and depression, smoking and elevated cholesterol.

Report Highlights

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Mild Cognitive Impairment - Pipeline Review, H2 2016, provides comprehensive information on the therapeutics under development for Mild Cognitive Impairment (Central Nervous System), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Mild Cognitive Impairment (Central Nervous System) pipeline guide also reviews of key players involved in therapeutic development for Mild Cognitive Impairment and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase III, Phase II, Phase I, IND/CTA Filed, Preclinical and Discovery stages are 1, 7, 8, 1, 11 and 1 respectively for Similarly, the Universities portfolio in Phase II and Discovery stages comprises 2 and 1 molecules, respectively for Mild Cognitive Impairment.

Mild Cognitive Impairment (Central Nervous System) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope

- The pipeline guide provides a snapshot of the global therapeutic landscape of Mild Cognitive Impairment (Central Nervous System).
- The pipeline guide reviews pipeline therapeutics for Mild Cognitive Impairment (Central Nervous System) by companies and universities/research institutes based on information derived from company and industry-specific sources.
- The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
- The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
- The pipeline guide reviews key companies involved in Mild Cognitive Impairment (Central Nervous System) therapeutics and enlists all their major and minor projects.
- The pipeline guide evaluates Mild Cognitive Impairment (Central Nervous System) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
- The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
- The pipeline guide reviews latest news related to pipeline therapeutics for Mild Cognitive Impairment (Central Nervous System)

Reasons To Buy

- Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
- Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
- Find and recognize significant and varied types of therapeutics under development for Mild Cognitive Impairment (Central Nervous System).
- Classify potential new clients or partners in the target demographic.
- Develop tactical initiatives by understanding the focus areas of leading companies.
- Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics.
- Formulate corrective measures for pipeline projects by understanding Mild Cognitive Impairment (Central Nervous System) pipeline depth and focus of Indication therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

 Table of Contents

Table of Contents 2
List of Tables 7
List of Figures 8
Introduction 9
Global Markets Direct Report Coverage 9
Mild Cognitive Impairment Overview 10
Therapeutics Development 11
Pipeline Products for Mild Cognitive Impairment - Overview 11
Pipeline Products for Mild Cognitive Impairment - Comparative Analysis 12
Mild Cognitive Impairment - Therapeutics under Development by Companies 13
Mild Cognitive Impairment - Therapeutics under Investigation by Universities/Institutes 15
Mild Cognitive Impairment - Pipeline Products Glance 16
Late Stage Products 16
Clinical Stage Products 17
Early Stage Products 18
Mild Cognitive Impairment - Products under Development by Companies 19
Mild Cognitive Impairment - Products under Investigation by Universities/Institutes 21
Mild Cognitive Impairment - Companies Involved in Therapeutics Development 22
AbbVie Inc 22
AgeneBio Inc. 23
Avraham Pharmaceuticals Ltd. 24
CereSpir Incorporated 25
Eisai Co., Ltd. 26
Eli Lilly and Company 27
Ensol Biosciences Inc. 28
Genzyme Corporation 29
IntelGenx Corp. 30
Krenitsky Pharmaceuticals Inc. 31
Nanotherapeutics, Inc. 32
Neuron Biopharma SA 33
Octapharma AG 34
Sage Therapeutics, Inc. 35
Suven Life Sciences Ltd. 36
Takeda Pharmaceutical Company Limited 37
Therapix Biosciences Ltd. 38
Mild Cognitive Impairment - Therapeutics Assessment 39
Assessment by Monotherapy Products 39
Assessment by Target 40
Assessment by Mechanism of Action 42
Assessment by Route of Administration 44
Assessment by Molecule Type 46
Drug Profiles 48
ABT-957 - Drug Profile 48
Product Description 48
Mechanism Of Action 48
R&D Progress 48
BAN-2401 - Drug Profile 49
Product Description 49
Mechanism Of Action 49
R&D Progress 49
CSP-1103 - Drug Profile 51
Product Description 51
Mechanism Of Action 51
R&D Progress 51
CSTI-200 - Drug Profile 53
Product Description 53
Mechanism Of Action 53
R&D Progress 53
DAOI-B - Drug Profile 54
Product Description 54
Mechanism Of Action 54
R&D Progress 54
dronabinol - Drug Profile 55
Product Description 55
Mechanism Of Action 55
R&D Progress 55
immune globulin (human) - Drug Profile 56
Product Description 56
Mechanism Of Action 56
R&D Progress 56
KP-544 - Drug Profile 59
Product Description 59
Mechanism Of Action 59
R&D Progress 59
ladostigil tartrate - Drug Profile 60
Product Description 60
Mechanism Of Action 60
R&D Progress 60
levetiracetam - Drug Profile 62
Product Description 62
Mechanism Of Action 62
R&D Progress 62
LY-2599666 - Drug Profile 64
Product Description 64
Mechanism Of Action 64
R&D Progress 64
LY-3002813 - Drug Profile 65
Product Description 65
Mechanism Of Action 65
R&D Progress 65
LY-3303560 - Drug Profile 66
Product Description 66
Mechanism Of Action 66
R&D Progress 66
montelukast sodium - Drug Profile 67
Product Description 67
Mechanism Of Action 67
R&D Progress 67
Moriah-1000 - Drug Profile 68
Product Description 68
Mechanism Of Action 68
R&D Progress 68
NPS-0158 - Drug Profile 69
Product Description 69
Mechanism Of Action 69
R&D Progress 69
NPS-0163 - Drug Profile 70
Product Description 70
Mechanism Of Action 70
R&D Progress 70
NST-0037 - Drug Profile 71
Product Description 71
Mechanism Of Action 71
R&D Progress 71
NST-0076 - Drug Profile 72
Product Description 72
Mechanism Of Action 72
R&D Progress 72
NST-0078 - Drug Profile 73
Product Description 73
Mechanism Of Action 73
R&D Progress 73
NTC-942 - Drug Profile 74
Product Description 74
Mechanism Of Action 74
R&D Progress 74
Peptides to Agonize Insulin Receptor for Mild Cognitive Impairment and Alzheimer's Disease - Drug Profile 76
Product Description 76
Mechanism Of Action 76
R&D Progress 76
pioglitazone hydrochloride - Drug Profile 77
Product Description 77
Mechanism Of Action 77
R&D Progress 77
sargramostim - Drug Profile 79
Product Description 79
Mechanism Of Action 79
R&D Progress 79
sepranolone - Drug Profile 81
Product Description 81
Mechanism Of Action 81
R&D Progress 81
Small Molecule to Agonize GABRA5 Receptor for CNS Disorders - Drug Profile 88
Product Description 88
Mechanism Of Action 88
R&D Progress 88
SUVN-501 - Drug Profile 89
Product Description 89
Mechanism Of Action 89
R&D Progress 89
SUVN-502 - Drug Profile 91
Product Description 91
Mechanism Of Action 91
R&D Progress 91
SUVN-507 - Drug Profile 93
Product Description 93
Mechanism Of Action 93
R&D Progress 93
SUVN-512 - Drug Profile 94
Product Description 94
Mechanism Of Action 94
R&D Progress 94
TAK-071 - Drug Profile 95
Product Description 95
Mechanism Of Action 95
R&D Progress 95
tropisetron hydrochloride - Drug Profile 96
Product Description 96
Mechanism Of Action 96
R&D Progress 96
Mild Cognitive Impairment - Dormant Projects 97
Mild Cognitive Impairment - Discontinued Products 99
Mild Cognitive Impairment - Product Development Milestones 100
Featured News & Press Releases 100
Aug 22, 2016: IntelGenx Announces Successful Clinical Study for Montelukast for the Treatment of Degenerative Diseases of the Brain 100
Jul 13, 2016: IntelGenx to Initiate Phase 1 Trial of Montelukast 100
Jul 28, 2015: Avraham Pharmaceuticals Announces Successful Second Interim Results in Phase 2b Study of Ladostigil for the Treatment of Mild Cognitive Impairment 101
Jul 14, 2015: CereSpir Obtains New Patent From USPTO Covering the Optimal Synthetic Route for Commercial Manufacture of CSP-1103 in Late Stage Development to Slow the Progression of Mild Cognitive Impairment Due to Alzheimer's Disease 102
Jul 01, 2015: CereSpir Submits Special Protocol Assessment Request to FDA for a Phase 3 Clinical Trial to Test the Ability of CSP-1103 to Slow the Progression of Mild Cognitive Impairment Due to Alzheimer's Disease 102
Jul 08, 2014: Avraham Pharmaceuticals Announces Successful Interim Results in Phase 2b Study of Ladostigil for the Treatment of MCI 103
Jul 26, 2013: CERESPIR INCORPORATED IS PLEASED WITH POSITIVE INTERIM PHASE 2 RESULTS FOR CHF 5074 IN PATIENTS WITH MILD COGNITIVE IMPAIRMENT, PRESENTED BY CHIESI AT THE AAIC 2013 MEETING IN BOSTON 104
May 17, 2012: Avraham Initiates Phase II Ladostigil Study For Treatment Of Mild Cognitive Impairment 105
Apr 14, 2010: Alzheimer Drug Co Avraham Pharmaceuticals Raises $9m 105
Jul 27, 2009: Suven Presented Positive Phase-I Clinical Data Of SUVN-502 For Alzheimer's Disease At ICAD 2009, Vienna, Austria. 106
Apr 09, 2009: Suven Completes Phase I Clinical Trials Multiple Ascending Dose Of SUVN-502 In Switzerland 106
Oct 13, 2008: Suven Announces That SUVN-502 Data Is Being Presented At 16th BioPartnering In London 107
Sep 29, 2008: Suven Completes Phase-I Clinical Trials Single Ascending Dose Of Suvn-502 In Switzerland 108
Sep 25, 2008: Suven Life Sciences Ltd. Announces DCGI Nod To Conduct Phase-I Clinical Trials Of Suvn-502 For Alzheimer'S Disease 108
Aug 04, 2008: Suven Life Sciences Presents Positive Preclinical Data for Suvn-502 at Alzheimer'S Conference, Chicago and Drug Discovery Conference, Boston 109
Appendix 110
Methodology 110
Coverage 110
Secondary Research 110
Primary Research 110
Expert Panel Validation 110
Contact Us 110
Disclaimer 111

List of Tables

Number of Products under Development for Mild Cognitive Impairment, H2 2016 11
Number of Products under Development for Mild Cognitive Impairment - Comparative Analysis, H2 2016 12
Number of Products under Development by Companies, H2 2016 14
Number of Products under Investigation by Universities/Institutes, H2 2016 15
Comparative Analysis by Late Stage Development, H2 2016 16
Comparative Analysis by Clinical Stage Development, H2 2016 17
Comparative Analysis by Early Stage Development, H2 2016 18
Products under Development by Companies, H2 2016 19
Products under Development by Companies, H2 2016 (Contd..1) 20
Products under Investigation by Universities/Institutes, H2 2016 21
Mild Cognitive Impairment - Pipeline by AbbVie Inc, H2 2016 22
Mild Cognitive Impairment - Pipeline by AgeneBio Inc., H2 2016 23
Mild Cognitive Impairment - Pipeline by Avraham Pharmaceuticals Ltd., H2 2016 24
Mild Cognitive Impairment - Pipeline by CereSpir Incorporated, H2 2016 25
Mild Cognitive Impairment - Pipeline by Eisai Co., Ltd., H2 2016 26
Mild Cognitive Impairment - Pipeline by Eli Lilly and Company, H2 2016 27
Mild Cognitive Impairment - Pipeline by Ensol Biosciences Inc., H2 2016 28
Mild Cognitive Impairment - Pipeline by Genzyme Corporation, H2 2016 29
Mild Cognitive Impairment - Pipeline by IntelGenx Corp., H2 2016 30
Mild Cognitive Impairment - Pipeline by Krenitsky Pharmaceuticals Inc., H2 2016 31
Mild Cognitive Impairment - Pipeline by Nanotherapeutics, Inc., H2 2016 32
Mild Cognitive Impairment - Pipeline by Neuron Biopharma SA, H2 2016 33
Mild Cognitive Impairment - Pipeline by Octapharma AG, H2 2016 34
Mild Cognitive Impairment - Pipeline by Sage Therapeutics, Inc., H2 2016 35
Mild Cognitive Impairment - Pipeline by Suven Life Sciences Ltd., H2 2016 36
Mild Cognitive Impairment - Pipeline by Takeda Pharmaceutical Company Limited, H2 2016 37
Mild Cognitive Impairment - Pipeline by Therapix Biosciences Ltd., H2 2016 38
Assessment by Monotherapy Products, H2 2016 39
Number of Products by Stage and Target, H2 2016 41
Number of Products by Stage and Mechanism of Action, H2 2016 43
Number of Products by Stage and Route of Administration, H2 2016 45
Number of Products by Stage and Molecule Type, H2 2016 47
Mild Cognitive Impairment - Dormant Projects, H2 2016 97
Mild Cognitive Impairment - Dormant Projects (Contd..1), H2 2016 98
Mild Cognitive Impairment - Discontinued Products, H2 2016 99